Literature DB >> 13679630

Recombinant antibodies for the diagnosis and treatment of cancer.

Jürgen Krauss1.   

Abstract

The advent of recombinant antibody technology led to an enormous revival in the use of antibodies as diagnostic and therapeutic tools for fighting cancer. This review provides a brief historical sketch of the development of recombinant antibodies for the diagnosis and immunotherapy of cancer and summarizes the most significant clinical data for the best established reagents to date. It also discusses clinically relevant aspects of the use of recombinant antibodies in cancer patients.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 13679630     DOI： 10.1385/MB:25:1:1

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN： 1073-6085            Impact factor:   2.695


  200 in total

1.  "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.

Authors:  Philip Tan; David A Mitchell; Timothy N Buss; Margaret A Holmes; Claudio Anasetti; Jefferson Foote
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

2.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  A comparison of strategies to stabilize immunoglobulin Fv-fragments.

Authors:  R Glockshuber; M Malia; I Pfitzinger; A Plückthun
Journal:  Biochemistry       Date:  1990-02-13       Impact factor: 3.162

4.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

5.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Cancer Immunol Immunother       Date:  2000-03       Impact factor: 6.968

6.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

7.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments.

Authors:  C A Kettleborough; K H Ansell; R W Allen; E Rosell-Vives; D H Güssow; M M Bendig
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

9.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

10.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

Authors:  U Brinkmann; Y Reiter; S H Jung; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779
View more
  4 in total

1.  Transgenic tobacco plants expressing a dimeric single-chain variable fragment (scfv) antibody against Salmonella enterica serotype Paratyphi B.

Authors:  Shokouh Makvandi-Nejad; Michael D McLean; Tomoko Hirama; Kurt C Almquist; C Roger Mackenzie; J Christopher Hall
Journal:  Transgenic Res       Date:  2005-10       Impact factor: 2.788

2.  Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.

Authors:  Dovile Stravinskiene; Aiste Sliziene; Lina Baranauskiene; Vilma Petrikaite; Aurelija Zvirbliene
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 3.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

4.  Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies.

Authors:  Renjian Hu; Zhen Dong; Kui Zhang; Guangzhao Pan; Chongyang Li; Hongjuan Cui
Journal:  Viruses       Date:  2020-03-19       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.